Baxter’s Factor IX Product For Hemophilia B Advances To FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Baxter’s treatment could soon compete with Pfizer’s BeneFIX, the only commercially available recombinant factor IX protein for hemophilia B in the U.S. At least two other recombinant factor IX products are in Phase III trials.